Serotonin-Transporter Binding in Tourette-Syndrome and Obsessive-Compulsive Disorder before and during Treatment with SRI: a I-123-ADAM-SPECT-Study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-001411-22-DE

Enrollment

Registered

2005-10-12

Start date

2006-02-15

Completion date

Unknown

Last updated

2014-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsessive compulsive disorder

Interventions

Product Name: Cipralex Pharmaceutical Form: Tablet INN or Proposed INN: Escitalopram CAS Number: 219861-08-2 Current Sponsor code: ADAM-SPECT 3792 Concentration unit: mg milligram(s) Concentration typ

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Diagnosis of obsessive compulsive disorder according to DSM IV-TR or Tourette syndrome according to DSM IV-TR with obsessive compulsive behaviour Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Underaged, pregnant and breastfeeding women, treatment with any drug affecting the serotonergic system within the last 6 months

Design outcomes

Primary

Measure	Time frame
Main Objective: Effectiveness of Escitalopram in obsessive compulsive disorder;Secondary Objective: Effectiveness of Escitalopram in the treatment of obsessive compulsive behaviour in Tourette syndrome;Primary end point(s): Re-evaluation of the patients after 12 to 16 months of treatment with Escitalopram	—

Countries

Germany

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026